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Abstract
Fungal infections are increasing and their treatment 
is difficult, because the most widely used antifungal 
drugs are relatively toxic and have serious side effects. 
Therefore, interest has focused on safely applicable 
and clinically introduced non-antifungal drugs, which 
have potent antifungal activity. Statins were originally 
used as cholesterol lowering agents in human therapy, 
but recent studies demonstrated their in vitro  anti-
fungal activity against yeasts and filamentous fungi. 
This indicated their potential application, alone or in 
combination with other drugs, in the treatment of such 
diseases. Their effective concentrations are higher than 
their maximum achievable serum levels; therefore, the 
application of statins for the treatment of invasive fun-
gal infections is only possible in combination with anti-
fungal agents. These synergistic combinations establish 
a basis for a new safely applicable therapy. This review 
focuses on the antifungal activity of statins alone and in 
combination with antifungal and non-antifungal drugs, 
and their possible application in clinical therapy.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
The incidence of  invasive fungal infections (IFIs) is 
increasing because of  the growing number of  immu-
nocompromised hosts and the occurrence of  antibiotic 
resistant strains. The major risk factors for these diseases 
are the administration of  broad-spectrum antibiotics, cor-
ticosteroids and cytotoxic agents, intravenous catheters, 
invasive medical procedures, human immunodeficiency 
virus infection, poorly controlled diabetes mellitus, hema-
tological malignancy, solid organ or bone marrow trans-
plantation, steroid use, metabolic acidosis, deferoxamine 
therapy, and severe and prolonged neutropenia[1,2]. Treat-
ment of  IFIs is difficult, because the most widely applied 
antifungal drugs [e.g. amphotericin B (AMB)] for treat-
ment of  such disease are relatively toxic and have serious 
side effects. Therefore, there is a substantial interest in 
clinically introduced non-antifungal drugs that have po-
tent antifungal activity and/or can act synergistically with 
antifungal agents to allow a decrease in their therapeutic 
concentrations. Such compounds would form the basis 
of  a less toxic therapy[3]. Statins are interesting from this 
respect, as they have effective antifungal potential against 
both yeast and filamentous fungi; furthermore, they can 
be combined with clinically used antifungal agents.
STATINS
History of statins
Statins were discovered as cholesterol lowering drugs in 
the 1970s, and are the most widely prescribed medica-
tions worldwide[4].
EDITORIAL
4 December 30, 2011|Volume 1|Issue 1|WJCID|www.wjgnet.com
Galgóczy L et al . Statins as antifungal agents
Statins are metabolites of  microorganisms (mevas-
tatin, MEV; lovastatin, LOV; simvastatin, SIM and prava-
satin, PRA) or fully synthetic compounds (atorvastatin, 
ATO; cerivastatin, CER; fluvastatin, FLV; pitavastatin, 
PIT; and rosuvastatin, ROS). The natural statins are 
substituted hexahydronaphthalene lactones. The first de-
scribed statin, MEV, was isolated as a secondary metabo-
lite of  a Penicillium citrinum strain. Subsequently, further in-
tensive fungal screenings for similar compounds revealed 
that a strain of  both Aspergillus terreus and Monascus ruber 
produce a more efficient statin, LOV[5]. SIM is a post-
methylated derivative of  LOV[6], and PRA was isolated 
from the fermentation broth of  an Actinobacteria spe-
cies, Nocardia autotrophica[7].
After successful clinical trials of  the natural statins, 
pharmaceutical companies introduced more effective and 
safer fully synthetic statins. The structures of  synthetic 
statins are dissimilar and are different from the natural 
statins, except for the 3-hydroxy-3-methylglutaryl-coen-
zyme A (HMG-CoA)-like moiety, which is responsible 
for HMG-CoA reductase inhibition, which, indirectly, 
results in their cholesterol lowering effects[8]. FLV was the 
first fully synthetic statin, followed by ATO, CER, PIT, 
and ROS[5]. CER has been withdrawn from the market 
because of  its serious adverse effect (fatal rhabdomyoly-
sis)[9].
Statins were observed to have unexpected antifungal 
effects and their potential application in the treatment of  
fungal diseases has been intensively studied.
Mechanism of statins’ effects
Statins are competitive inhibitors of  HMG-CoA reduc-
tase, which catalyses the conversion of  HMG-CoA to 
mevalonate, a rate-limiting step in the isoprenoid bio-
synthetic pathway, which is involved in the synthesis of  
cholesterol in humans and ergosterol in fungi[10]. Statins 
compete with the natural substrate for the enzyme’s ac-
tive site, preventing the formation of  a functional enzyme 
structure with reversible binding[11].
Thus, the effects of  statins are connected with the 
inhibition of  the synthesis of  important isoprenoids, e.g. 
farnesyl pyrophosphate and geranylgeranyl pyrophosphate, 
which are important lipid attachments for the γ subunit 
of  heterotrimeric G-proteins[12], guanosine triphosphate-
binding protein Ras, and Ras-like proteins (Rho, Rab, Rac, 
Ral, or Rap)[12-14]. Thus, statins act as inhibitors of  some 
G-protein actions and Ras or Ras-like signaling, which af-
fect several important bioprocesses[15].
Figure 1 summarizes the metabolic pathway of  sterols 
and the impact of  statins in their biosynthesis[16,17].
ANTIFUNGAL ACTIVITY OF STATINS
The in vitro antifungal activity of  statins against yeasts and 
filamentous fungal isolates has been frequently reported, 
and all the studies propose their potential application, 
alone or in combination, in clinical therapy. The different 
fungi are not equally sensitive to statins in vitro, e.g. SIM 
exhibits the strongest antifungal activity against yeasts 
compared to filamentous fungi, whereas the reverse is 
true for FLV[18]. The natural statins (e.g. SIM and LOV) 
mainly effect their antifungal activity in their active me-
tabolite forms (hydrolysis of  the lactone ring at pH 10), 
and they proved to be less effective as pro-drugs[18,19]. 
Generally, the synthetic statins are more effective than 
the natural ones[18,19].
Antifungal activity of statins against yeasts
Statins exhibit fungicidal or fungistatic effects against 
yeasts in a dose dependent-manner. Data concerning the 
antifungal activity of  various statins against yeasts are 
available for Candida albicans (C. albicans), Candida glabrata 
(C. glabrata), Candida krusei, Candida parapsilosis, Candida 
tropicalis, Cryptococcus neoformans (C. neoformans), and Sac-
charomyces cerevisiae[18,20-29]. These studies demonstrated 
that the various statins exhibit different antifungal effects 
against yeasts. SIM displayed the strongest antifungal 
activity, followed by FLV, ATO, ROS, and LOV. PRA 
proved to be completely ineffective against them. The 
antifungal activity of  FLV is dependent on the pH of  the 
medium[27]. Table 1 shows the available minimal inhibito-
ry concentration (MIC) values of  the investigated statins 
against yeast species.
The growth inhibition effect of  statins on yeast cells 
is related to the decreasing ergosterol level, which occurs 
because of  the inactivation of  HMG-CoA reductase in-
activation by statins in the isoprenoid biosynthetic path-
way[16]. Ergosterol is a main constituent of  the lipid layer 
of  fungal plasma membranes, and the antifungal effect 
might arise from decreased membrane fluidity in the yeast 
cells[24]. This assumption is confirmed by the observa-
tion that supplementation with ergosterol or cholesterol 
reduced the antifungal effect of  statins[20,25,26], and that 
C. albicans transformed from the yeast cell form to the 
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Figure 1  Metabolic pathway of sterols and the impact of statins in their 
bioprocess[16,17].
pseudomycelial form upon exposure to LOV[24]. It is also 
proposed that antimicrobial activity based on the loss of  
mitochondrial DNA, and thus the respiratory function 
of  the cell, occurs in the presence of  statins[16]. Indirectly, 
the antifungal effect of  statins might come from their 
negative influence on the cell signaling by the inhibition 
of  the synthesis of  lipid attachments for the γ subunit of  
heterotrimeric G-proteins[15], and on the cell proliferation 
and differentiation through inhibition of  the synthesis of  
important isoprenoids[30]. LOV does not cause apoptotic 
cell death in yeasts compared to filamentous fungi[24,31]. 
Antifungal activity of statins against filamentous fungi
The inhibition activity of  statins on the growth of  filamen-
tous fungi was revealed in the cases of  several zygo-[18,19,28,31-35] 
and ascomycetous fungal species[18,25,28,29,36,37]. Only one article 
reports the antifungal activity of  FLV against a Heterokon-
tophyta fungal species, Pythium insidiosum[38]. In contrast to 
its activity against yeasts, FLV displayed the strongest an-
tifungal activity, followed by ROS, SIM, LOV, and ATO. 
PRA also proved to be ineffective against them. Table 2 
summarizes the determined MIC values of  statins against 
different filamentous fungal species.
Beyond to the harmful effects on membrane fluidity 
and the synthesis of  important isoprenoids for cell sig-
naling and vital processes (such as cell proliferation and 
differentiation), and protein prenylation[16], statins induce 
apoptosis-like cell death in filamentous fungi[15,30,31]. The 
molecular mechanisms underlying the different levels of  
fungal resistance to statins are unknown. It is hypoth-
esized that the resistance is connected with the different 
copy numbers of  the HMG-CoA reductase gene (hmgR) 
in the case of  filamentous species. This assumption is 
supported by the observation of  Lukács et al[39]. In their 
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Table 1  Determined minimal inhibitory concentration values (µg/mL) of different statins against Candida  species
Statin/species ATO FLV LOV PRA ROS SIM Ref.
Candida albicans 128   2�-128 �-64 > 128 128 8 [18,21,22,2�]
Candida glabrata   32      64-> 128 128 > 128 128 16-32 [18,21,2�]
Candida parapsilosis ND   64-128 ND ND ND ND [21]
Candida tropicalis ND   64-128 ND ND ND ND [21]
Cryptococcus neoformans ND 16-32 ND ND ND ND [21]
ATO: Atorvastatin; FLV: Fluvastatin; LOV: Lovastatin; PRA: Pravastatin; ROS: Rosuvastatin; SIM: Simvastatin; ND: Not determined.
Table 2  Determined minimal inhibitory concentration values (µg/mL) of different statins against filamentous fungal species
Statin/Species ATO FLV LOV PRA ROS SIM Ref.
Zygomycetes
   Absidia corymbifera       �61 > 2�-3.6   > �6   > �6        331        �61 [1�,3�]
   Absidia glauca ND           6.2� ND ND ND ND [3�]
   Cunninghamella bertholletiae ND ND 32-40 ND ND ND [33]
   Micromucor ramanniana ND > 2� ND ND ND ND [3�]
   Mortierella wolfii > 128 ND > 128 ND > 128 > 128 [34]
   Mucor circinelloides ND ND   �-40 ND ND ND [33]
   Mucor circinelloides f. lusitanicus ND > 2� ND ND ND ND [3�]
   Mucor hiemalis ND > 2� ND ND ND ND [3�]
   Mucor mucedo ND           6.2� ND ND ND ND [3�]
   Mucor racemosus ND    2� ND ND ND ND [3�]
   Mycotypha africana        8 ND > 128 ND        8 > 128 [34]
   Paecilomyces variotii      32    2�      64 > 128      32 8 [2�]
   Rhizomucor mieheii   > �6           6.2�      64-> 128   > �6        331   > �6 [1�,32,3�]
   Rhizomucor pusillus   > �6             3.12�     1-3.61   > �6        111        331 [1�,32,3�]
   Rhizopus homothallicus ND ND 40-�6 ND ND ND [33]
   Rhizopus microsporus var. oligosporus   > �6     �61   > �6   > �6   > �6   > �6 [1�]
   Rhizopus oryzae 32-�61 2-111   32-128 > 128 > 128 64-> �61 [18,1�,2�,33,3�]
   Rhizopus schipperae ND > 2� ND ND ND ND [3�]
   Rhizopus stolonifer      64 > 128      64 > 128 [34]
   Saksenaea vasiformis ND > 2� ND ND ND ND [3�]
   Syncephalastrum racemosum 32-> �6      331    16-> �6   > �6 32-> �6 8-> �6 [1�,34,3�]
Ascomycetes
   Aspergillus flavus > 128  128 > 128 > 128 > 128 > 128 [18,2�]
   Aspergillus fumigatus 64-> 2�6      2      2� > 128 128-> 2�6              6.2� [18,2�,37]
   Aspergillus spp. ND ND 16-2�6 ND ND 4-2�6 [36]
   Paecilomyces variotii      32    2�      64 > 128      32         8 [18]
Heterokontophyta
   Pythium insidiosum ND   16-64 ND ND ND ND [38]
1MIC�0 value. ATO: Atorvastatin; FLV: Fluvastatin; LOV: Lovastatin; PRA: Pravastatin; ROS: Rosuvastatin; SIM: Simvastatin; ND: Not determined.
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study, heterologous expression of  the Rhizomucor miehei 
hmgR gene in Mucor circinelloide lowered its sensitivity to 
statins compared to the untransformed strain. Further-
more, supplementation of  sterols to the medium re-
duces the antifungal activity of  statins, as in the case of  
yeasts[25].
ANTIFUNGAL ACTIVITY OF STATINS IN 
DRUG COMBINATIONS 
Statins are not applicable as single antifungal agents 
for the treatment of  IFI because their MICs are much 
higher (about 1 order of  magnitude) than their maximum 
achievable concentrations in human serum[11,40-45]. All the 
same, they should be promising agents in clinical prac-
tice because they can act additively or synergistically with 
antifungal agents, allowing substantial decreases in their 
therapeutic concentrations and their side effects[45]. Such 
combinations would be advantageous as the basis of  a 
less toxic antifungal therapy[3].
Combination with antifungal agents
Statins can interact synergistically with azole antifungal 
agents against yeasts and can reduce their growth sig-
nificantly. Fluconazole (FCZ) with LOV, and FCZ or 
itraconazole (ITZ) with FLV, interact synergistically on 
the growth of  Candida species[21,22]; however, interac-
tion was not demonstrated between PRA or FLV and 
FCZ[23]. FLV acted additively with AMB, FCZ, and ITZ 
against C. albicans and C. neoformans[21]. Both synergistic 
and additive effects were observed on the growth reduc-
tion of  C. albicans and C. glabrata when primycin (PN), a 
non-polyene macrolide lactone antibiotic complex, was 
combined with FLV, LOV, or SIM[18]. Additive interac-
tions were observed between AMB and ATO and ROS, 
and between nystatin (NYS) and FLV, LOV, ROS, and 
SIM in the case of  C. albicans and C. glabrata[28]. A recent 
comprehensive study, where the interaction was inves-
tigated between four different azole compounds (FCZ; 
ITZ; ketoconazole, KTZ; and miconazole; MCZ) and six 
different statins (ATO, FLV, LOV, PRA, ROS, and SIM), 
revealed synergistic and additive interaction between 
these compounds against C. albicans and C. glabrata[29]. 
Table 3 summarizes these interactions.
Synergistic and additive interactions were revealed be-
tween statins and antifungal agents in the case of  zygomy-
cetous fungal species[18,19,28,29,33]. Significant in vitro synergy 
between statins and azole antifungal agents was demon-
strated against several zygomycete fungi, though voricon-
azole itself  was ineffective[29,33]. Remarkable antifungal ef-
fects were observed on the growth of  Rhizopus oryze when 
PN was combined with statins in concentrations that 
could not inhibit the fungal growth alone[18]. In the case of  
this species, AMB and NYS also interacted additively with 
different statins[28]. In vitro, FLV and ROS acted synergisti-
cally and additively with AMB in inhibiting the growth of  
fungi belonging to Zygomycetes over their clinically avail-
able concentration ranges in human serum[19]. After in vivo 
tests, these concentration combinations may represent a 
promising basis for combined therapy in the treatment of  
invasive zygomycosis.
Synergistic and/or additive interaction of  AMB, ca-
spofungin, VCZ, PN with FLV on the growth reduction 
of  Aspergillus fumigatus was demonstrated[28,37]. AMB acted 
additively with ATO and FLV against Aspergillus flavus[28]. 
Synergistic interaction was observed between PN and 
FLV, LOV and SIM, and an additive interaction was ob-
served between AMB and ATO or SIM in the case of  
Paecilomyces variotii[18,28]. Additive and synergistic interactions 
were revealed between statins and azoles against A. flavus, 
A. fumigatus, and Paecilomyces variotii[29].
Terbinafine acted antagonistically in combination with 
FLV against P. insidiosum. Reduced antifungal activity was 
observed for their combination compared to when they 
were applied alone[38].
Combination with other drugs
Drug interactions were revealed between statins and non-
antifungal drugs, which have a secondary antifungal activity. 
An antifungal peptide secreted by Penicillium chrsyogenum 
(Penicillium chrsyogenum antifungal protein; PAF) and a hex-
asulfonated naphtylurea, suramin (originally applied as an 
agent for treatment of  parasitic infections) can decrease 
the growth of  zygomyceteous fungal species in the pres-
ence of  different statins[34,35]. The activities of  the statin-
PAF combinations on the different strains varied, and 
depended on the activities of  the components applied 
separately. When a strain was resistant to one of  the com-
ponents, significant interactions could not be detected. 
On the other hand, when a strain was sensitive to both 
types of  antifungal agents, synergistic or additive interac-
tions were detected[34]. Interactions were not detected be-
tween FLV and suramin if  the investigated strain proved 
to be insensitive to both compounds, but synergistic and 
additive interactions could be observed if  the fungus was 
sensitive to FLV and insensitive to suramin. Antagonistic 
interaction was observed if  the fungus was sensitive to 
both drugs[35].
These results are summarized in Table 4.
STATINS AS ANTIFUNGAL AGENTS IN 
CLINICAL THERAPY
A number of  studies detail the beneficial effects of  statins 
in transplant or non-transplant recipients with sepsis or in-
fection[16]. One theory of  the possible clinical therapy for 
invasive mould infection (IMI) among immunocompro-
mised patients was created based on the observation that 
this disease in patients with diabetes mellitus appears to be 
decreasing over recent years because of  the more frequent 
use of  statins in these patients[46]. This hypothesis is well 
supported by the above-mentioned in vitro susceptibility 
and drug interaction studies; however, a recent retrospec-
tive case-control study suggested that, despite evidence of  
in vitro activity, statins may not decrease risk of  IMI[47].
In consequence, because the in vitro observed MICs 
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Table 3  Revealed in vitro  interactions between statins and clinically used antifungal agents against different fungi
Species Antifungal agent Statin Interaction Ref.
Yeasts
   Candida albicans AMB ATO, FLV ADD [28,21]
FCZ, ITZ, KTZ ATO ADD [2�]
FCZ, ITZ FLV ADD, SYN, NI [21,23,2�]
LOV SYN, ADD [22,2�]
FCZ, ITZ, KTZ, MCZ PRA NI [23,2�]
FCZ,KTZ ROS ADD [2�]
FCZ, ITZ, KTZ SIM ADD [2�]
ITZ, KTZ, MCZ FLV, LOV ADD [2�]
ITZ,MCZ ROS SYN, ADD [2�]
MCZ ATO,SIM SYN, ADD [2�]
PN, NYS FLV, LOV, SIM ADD [18,28]
   Candida glabrata AMB ATO, ROS ADD [18]
FCZ ATO SYN, ADD [2�]
FCZ, ITZ FLV ADD, NI [21,2�]
FCZ LOV SYN, ADD [2�]
FCZ, ITZ PRA NI [2�]
FCZ, ITZ, KTZ, MCZ ROS, SIM ADD [2�]
ITZ, KTZ, MCZ ATO, FLV, ROS ADD [2�]
KTZ, MCZ PRA ADD [2�]
PN ATO, FLV ADD [18]
LOV, SIM ADD, SYN [18]
NYS LOV, ROS ADD [28]
   Candida parapsilosis FCZ, ITZ FLV ADD, SYN [21]
   Candida tropicalis FCZ FLV SYN [21]
ITZ FLV ADD, SYN [21]
   Cryptococcus neoformans FCZ, ITZ FLV ADD, SYN [21]
AMB FLV ADD [21]
Filamentous fungi-Zygomycetes
   Absidia corymbifera AMB ROS ADD, SYN [1�]
   Cunninghamella bertholletiae VCZ LOV SYN [33]
   Mucor circinelloides VCZ LOV SYN [33]
   Rhizomucor mieheii AMB FLV, ROS ADD, SYN [1�]
   Rhizopus homothallicus VCZ LOV SYN [33]
   Rhizopus microsporus var. oligosporus AMB FLV, ROS ADD, SYN [1�]
   Rhizopus oryzae AMB FLV, ROS ADD, SYN [1�,28]
ATO, SIM ADD [28]
FCZ FLV NI [2�]
FCZ, ITZ, MCZ LOV ADD [2�]
ITZ, KTZ ATO, FLV, ROS SYN, ADD [2�]
ITZ, KTZ, MCZ PRA NI [2�]
ITZ, KTZ SIM NI [2�]
KTZ LOV NI [2�]
MCZ ATO NI [2�]
FLV, ROS, SIM ADD [2�]
NYS ATO, FLV, LOV ADD [28]
PN ATO ADD [18]
LOV, ROS SYN [18]
VCZ LOV SYN [33]
   Syncephalastrum racemosum AMB FLV, ROS ADD, SYN [28]
Filamentous fungi-Ascomycetes
   Aspergillus flavus AMB, PN FLV ADD, SYN [18,28]
ITZ ATO SYN [2�]
ITZ, KTZ, MCZ FLV SYN, ADD [2�]
ITZ LOV ADD [2�]
ITZ, KTZ PRA NI [2�]
ITZ ROS ADD [2�]
ITZ, MCZ SIM ADD [2�]
KTZ ATO, ROS SYN, ADD [2�]
SIM NI [2�]
MCZ ATO, LOV, ROS NI [2�]
PRA ADD [2�]
   Aspergillus fumigatus AMB ATO, FLV ADD, SYN [28,37]
CFG, VCZ FLV SYN [37]
FCZ, ITZ ATO SYN [2�]
FCZ, ITZ, MCZ FLV ADD [2�]
FCZ LOV SYN [2�]
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FCZ SIM SYN, ADD [2�]
ITZ, KTZ, MCZ LOV, SIM ADD [2�]
PRA NI [2�]
ITZ ROS SYN, ADD [2�]
KTZ, MCZ ATO SYN, ADD [2�]
KTZ FLV SYN, ADD [2�]
KTZ, MCZ ROS ADD [2�]
   Paecilomyces variotii AMB ATO,SIM ADD [28]
PN FLV, LOV, SIM SYN [18]
Filamentous fungi-Heterokontophyta
   Pythium insidiosum TBF FLV ANT [37]
ADD: Additive interaction; AMB: Amphotericin B; ANT: Antagonism; ATO: Atorvastatin; CFG: Capofungin; FCZ: Fluconazole; FLV: Fluvastatin; 
ITZ: Itraconazole; KTZ: Ketoconazole; LOV: Lovastatin; MCZ: Miconazole; NI: No interaction; NYS: Nystatin; PN: Primycin; PRA: Pravastatin; ROS: 
Rosuvastatin; SIM: Simvastatin; SYN: Synergistic interaction; TBF: Terbinafine; VCZ: Voriconazole.
Table 4  Revealed in vitro  interactions between statins and 
non-antifungal drugs against zygomycetous fungi
Species Non-
antifungal 
drug
Statin Interaction Ref.
Zygomycetes
   Absidia corymbifera SUR FLV SYN [3�]
   Absidia glauca SUR FLV ANT [3�]
   Micromucor ramanniana SUR FLV SYN [3�]
   Mucor circinelloides f. 
   lusitanicus
SUR FLV ADD, SYN [3�]
   Mucor racemosus SUR FLV ANT [3�]
   Mycotypha africana PAF ATO, SIM ADD [34]
LOV, ROS ADD, SYN [34]
   Rhizomucor mieheii SUR FLV ANT [3�]
   Rhizomucor pusillus SUR FLV ANT [3�]
   Rhizopus oryzae SUR FLV ADD, SYN [3�]
   Rhizopus schipperae SUR FLV ADD, SYN [3�]
   Saksanaea vasiformis SUR FLV ADD, SYN [3�]
   Syncephalastrum 
   racemosum
PAF ATO ADD, SYN [34]
ROS, SIM SYN [34]
SUR FLV ADD, SYN [3�]
ADD: Additive interaction; ANT: Antagonism; ATO: Atorvastatin; FLV: 
Fluvastatin; LOV: Lovastatin; PAF: Penicillium chrysogenum antifungal 
protein; ROS: Rosuvastatin; SIM: Simvastatin; SUR: Suramin; SYN: 
Synergistic interaction.
of  statins are higher than their concentrations achievable 
in human serum, their potential application to prevent or 
treat IMIs is only possible in combination with antifungal 
agents[45]. In clinical practice, the administration of  statins 
together with antifungals, which are metabolized by dif-
ferent cytochrome P450 (CYP450) isoenzymes in the 
liver, suggests that the drug interactions with the CYP 
system and the serious adverse effects (e.g. myopathy) are 
avoidable[45].
FUTURE PROSPECTIVES
The number of  antifungal agents available for treatment 
of  IFIs is limited, and their use has been restricted be-
cause of  their toxicity or unfavorable pharmacokinetic 
profiles[3]. Hence, research interest has focused on safe, 
non-antifungal drugs that are used in clinical practice and 
have antifungal activity.
The observed in vitro antifungal activities of  statins 
and their combinations with clinically antifungal agents 
would create new therapies for the treatment of  IFI, 
without serious side effects. However, there are some fac-
tors in their combined application that require increased 
attention in immunocompromised hosts. As a conse-
quence of  the pleiotropic beneficial effects of  statins 
beyond their lipid lowering attributes, there is a decreased 
risk of  chronic renal failure and an improved endothelial 
dysfunction)[16]. Importantly, the administration of  statins 
together with antifungals that are predominantly me-
tabolized by the same CYP450 isoenzymes in the liver is 
contraindicated, because such drug interactions with the 
CYP system may cause serious adverse effects[45].
Further studies, for example, in vivo animal model ex-
periments, are needed to evaluate the practical efficiency 
and possible triggered side effects of  statin-antifungal 
drug combinations.
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